These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21440506)

  • 1. Androgen deprivation before prostate radiotherapy: how long is long enough?
    Parker C
    Lancet Oncol; 2011 May; 12(5):411-2. PubMed ID: 21440506
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
    Roach M; DeSilvio M; Lawton C; Uhl V; Machtay M; Seider MJ; Rotman M; Jones C; Asbell SO; Valicenti RK; Han S; Thomas CR; Shipley WS;
    J Clin Oncol; 2003 May; 21(10):1904-11. PubMed ID: 12743142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant medical therapy for prostate cancer.
    Sumey C; Flaig TW
    Expert Opin Pharmacother; 2011 Jan; 12(1):73-84. PubMed ID: 21118060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of nodal positive prostatic carcinoma: when should hormone therapy be started?].
    Zierhut D
    Strahlenther Onkol; 1998 Jul; 174(7):382-3. PubMed ID: 9689961
    [No Abstract]   [Full Text] [Related]  

  • 8. Long- or short-term hormones for locally advanced prostate cancer?
    Brower V
    J Natl Cancer Inst; 2009 Dec; 101(23):1606-8. PubMed ID: 19910554
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.
    Langenhuijsen JF; van Lin EN; Hoffmann AL; Spitters-Post I; Alfred Witjes J; Kaanders JH; Mulders PF
    Urol Oncol; 2011; 29(1):52-7. PubMed ID: 19523856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
    Malik R; Jani AB; Liauw SL
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
    Lam ET; Glodé LM
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The question of intermittent hormonal treatment of cancer of the prostate].
    Boca P
    Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121
    [No Abstract]   [Full Text] [Related]  

  • 13. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competing risks for patients with localized prostate cancer.
    Seidenfeld J; Samson DJ; Albertsen PC
    J Natl Cancer Inst; 2007 Oct; 99(20):1498-9. PubMed ID: 17925533
    [No Abstract]   [Full Text] [Related]  

  • 15. Biased hormonal therapy duration analysis makes results uninterpretable.
    Tangen CM; Goldman BH; Swanson GP; Thompson IM
    J Clin Oncol; 2009 Nov; 27(33):e203; author reply e204. PubMed ID: 19786655
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen deprivation therapy and prostate cancer duration.
    Williams SG; Pickles T; Buyyounouski MK
    J Clin Oncol; 2009 Dec; 27(34):e228; author reply e229. PubMed ID: 19884533
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quality of life of patients with locally-advanced prostate cancer as a criterium of therapeutic effectiveness].
    Kaprin AD; Kostin AA; Tsybul'skiĭ AD
    Vopr Onkol; 2009; 55(3):285-90. PubMed ID: 19670727
    [No Abstract]   [Full Text] [Related]  

  • 19. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
    Tombal B
    Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.